The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Eli Lilly has named Winselow Tucker as President and General Manager for India. Tucker will oversee operations, including the Lilly India commercial organization and the Lilly Capability Centre India.

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

The main growth driver for Eli Lilly is the successful incretin portfolio, specifically the duo Mounjaro and Zepbound. Mounjaro's Q3 2024 performance was nothing short of exceptional, with global ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

Eli Lilly pre-announced the following drug numbers for Q4: Mounjaro — $3.5 billion, up from $3.1 billion in Q3 Zepbound — $1.9 billion, up from $1.26 billion in Q3. The biopharma reported ...

Eli Lilly forecasted its 2024 revenue to be around $45 billion, which falls $400 million short of the previously projected range of $45.4 to $46.6 billion. The company's Q4 GLP-1 revenue is ...